NEW DELHI : The covid-19 pandemic has highlighted the need for Indian companies and research organizations to collaborate with the government to develop new drugs in order to meet future health crises, Glenmark chairman and managing director Glenn Saldanha said in an email interview for Mint’s Pivot or Perish series.Saldanha said the company had expected competition for favipiravir, the antiviral drug to treat mild to moderate covid-19 patients, and was working to invest more in setting up active pharmaceutical ingredient (API) manufacturing plants in India following covid-19 disruptions in China.
Edited excerpts:What has been the impact of covid-19 and the subsequent lockdown on Glenmark? What were the lessons?For Glenmark, as well as most.